Posted on 12/12/02
Biovail takes stake in generic Prilosec heartburn drug
Biovail Corp. has taken a stake in the new generic version of heartburn blockbuster Prilosec as part of a $190-million (U.S.) acquisition of the closely held Pharma Pass group of companies.
The full text of this article has 506 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now



